Model shows nivolumab plus ipilimumab cost effective in mRCCFebruary 25, 2019Practice ManagementGenitourinary CancerRenal Cell CarcinomaImmuno-oncology
ZUMA-1 update: Axi-cel responses persist at 2 yearsFebruary 24, 2019Lymphoma & Plasma Cell DisordersImmuno-oncology
Dual-targeted CAR T shows ‘clinical signal’ in NHLFebruary 24, 2019Lymphoma & Plasma Cell DisordersImmuno-oncology
First-line avelumab/axitinib for RCC benefits wide range of patientsFebruary 21, 2019Renal Cell CarcinomaGenitourinary CancerImmuno-oncology
CAR T-cell therapies difficult to compareFebruary 16, 2019Immuno-oncologyLymphoma & Plasma Cell Disorders
CMS proposes coverage of CAR T-cell therapy in trialsFebruary 15, 2019Practice ManagementImmuno-oncologyImmunotherapyGene Therapy
Pembrolizumab-axitinib nearly halves risk of death in RCCFebruary 12, 2019Renal Cell CarcinomaGenitourinary CancerImmuno-oncology
PD-1 blockade plus CD19 CAR T boosts CAR T-cell persistenceFebruary 8, 2019PediatricsLeukemia, Myelodysplasia, TransplantationImmuno-oncology
Checkpoint inhibitors ‘viable treatment option’ in HIV-infected individualsFebruary 8, 2019Immuno-oncologyLung CancerSarcoma & GISTMelanoma
Enoblituzumab plus pembrolizumab shows promise for select solid tumorsFebruary 7, 2019Lung CancerImmuno-oncologyHead & Neck/Thyroid Cancers
Immunotherapy’s cardiac effects require early monitoring, managementFebruary 5, 2019Immuno-oncologyImmunotherapyPatient & Survivor CareMelanomaLeukemia, Myelodysplasia, Transplantation
The personal cancer vaccine NEO-PV-01 shows promise in metastatic cancersFebruary 1, 2019Immuno-oncologyMelanomaLung CancerGenitourinary Cancer
